ClinicalTrials.gg
RecruitingNCT07712419STAR-GNBUpdated Oct 20, 2026

Sonographic Thigh Adjustment Ratio and Subcutaneous Fat Thickness as Predictors of Genicular Nerve Block Response in Knee Osteoarthritis

An observational study in Knee Osteoarthritis and Chronic Knee Pain, sponsored by Gaziosmanpasa Research and Education Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Gaziosmanpasa Research and Education Hospital · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 20, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 268 studies in Osteoarthritis, Knee with a site in Turkey — 52 open to participants now, 63 under way, 3 of them phase 3. Osteoarthritis, Knee · Turkey.

Planned enrollment
64th of 70
30 · median 84
Started
2026
with 37 others
Observational
70 of 268
20 open now
Primary completion
2027-02
later than 42 of 62 live
Registered
248th of 268
by date

Among the 268 studies in Osteoarthritis, Knee with a site in Turkey, this one is the 64th largest by planned enrollment of the 70 observational ones that give a count, is one of 38 that started in 2026, is one of 70 observational ones, reaches primary completion later than 42 of the 62 other live ones, and was the 248th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

52 of the 268 studies in Osteoarthritis, Knee with a site in Turkey are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Osteoarthritis, Knee with a site in Turkey, or all of them as a file.
02

Study summary

Knee osteoarthritis (KOA) is a leading cause of chronic pain and disability. Although genicular nerve block (GNB) is an effective treatment for many patients, treatment response varies considerably. Identifying imaging biomarkers that predict clinical response may improve patient selection and optimize treatment outcomes.

This prospective observational study aims to evaluate whether the Sonographic Thigh Adjustment Ratio (STAR), calculated as anterior quadriceps muscle thickness divided by body mass index (BMI), and subcutaneous fat thickness are associated with pain relief following genicular nerve block in patients with symptomatic knee osteoarthritis. Ultrasound measurements will be obtained before the procedure, and clinical outcomes will be assessed during follow-up. The primary objective is to determine whether sonographic muscle parameters can predict treatment response after GNB.

Read the detailed description

Knee osteoarthritis is one of the most common musculoskeletal disorders worldwide and is frequently associated with chronic pain, impaired mobility, and reduced quality of life. Genicular nerve block has become an established minimally invasive treatment for patients with persistent pain despite conservative management. However, substantial variability exists in treatment response, highlighting the need for reliable predictors of clinical success.

Recent studies have suggested that ultrasound-derived muscle measurements may provide objective information regarding muscle quality and sarcopenia. The Sonographic Thigh Adjustment Ratio (STAR), defined as anterior quadriceps muscle thickness normalized to body mass index (BMI), has been proposed as an ultrasound-based indicator of muscle mass. Nevertheless, its potential role in predicting the response to interventional pain procedures has not been investigated.

This prospective observational cohort study will enroll patients with symptomatic knee osteoarthritis who undergo ultrasound-guided genicular nerve block as part of routine clinical care. Before the procedure, ultrasound measurements of anterior quadriceps muscle thickness and subcutaneous fat thickness will be obtained. STAR will be calculated by dividing anterior quadriceps muscle thickness by BMI. Clinical outcomes will be assessed using validated pain and functional outcome measures during follow-up.

The primary objective is to evaluate whether STAR predicts treatment response after genicular nerve block. Secondary objectives include investigating the predictive value of quadriceps muscle thickness and subcutaneous fat thickness individually and exploring their relationship with pain reduction and functional improvement.

03

Conditions studied

  • Knee Osteoarthritis
  • Chronic Knee Pain

Keywords

  • Genicular Nerve Block
  • Knee Osteoarthritis
  • Ultrasonography
  • Sonographic Thigh Adjustment Ratio
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with symptomatic bilateral Kellgren-Lawrence grade 3-4 knee osteoarthritis referred from the Department of Physical Medicine and Rehabilitation to the Pain Medicine Clinic for ultrasound-guided genicular nerve block after failure of conservative treatment. Consecutive eligible patients meeting the inclusion criteria will be enrolled prospectively.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥45 years.
  • Symptomatic bilateral knee osteoarthritis with Kellgren-Lawrence grade 3 or 4.
  • Visual Analog Scale (VAS) pain score ≥4 at rest or during movement.
  • Scheduled to undergo first ultrasound-guided genicular nerve block.
  • No intra-articular knee injection within the previous 3 months.
  • Considered unsuitable for or awaiting total knee arthroplasty.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Inflammatory arthritis, rheumatoid arthritis, or crystal arthropathy.
  • Previous knee surgery or knee prosthesis.
  • Active local or systemic infection.
  • Anticoagulant therapy or bleeding disorders.
  • to (including uncontrolled diabetes mellitus).
  • Allergy to study medications.
  • Neurological disorders causing neuropathic knee pain.
  • Dementia or inability to complete study assessments.
  • Additional interventional procedures or surgery during follow-up.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Patients With Knee Osteoarthritis Undergoing Genicular Nerve Block

    Adults with symptomatic Kellgren-Lawrence grade 3-4 knee osteoarthritis undergoing ultrasound-guided genicular nerve block as part of routine clinical care. Participants undergo baseline ultrasonographic assessment of quadriceps muscle thickness, subcutaneous fat thickness, and calculation of the Sonographic Thigh Adjustment Ratio (STAR), followed by clinical follow-up at 1 and 3 months.

    Procedure: Ultrasound-Guided Genicular Nerve Block

Interventions

  • ProcedureUltrasound-Guided Genicular Nerve Block

    Ultrasound-guided genicular nerve block was performed as part of routine clinical care in patients with symptomatic knee osteoarthritis. The superomedial, superolateral, and inferomedial genicular nerves were targeted using a standardized ultrasound-guided technique. A standardized injectate consisting of bupivacaine, dexamethasone, and normal saline was administered to each target nerve. The procedure was performed by an experienced pain physician using the same protocol for all participants.

06

What researchers measure

Primary outcomes

  1. Treatment Response at 1 Month Following Genicular Nerve Block

    Treatment response will be defined as a ≥50% reduction in Visual Analog Scale (VAS) pain score from baseline at 1 month after ultrasound-guided genicular nerve block. The predictive value of baseline Sonographic Thigh Adjustment Ratio (STAR) for 1-month treatment response will be evaluated.

    Time frame: 1 month

Secondary outcomes

  1. Responder Pattern After Genicular Nerve Block

    Participants will be classified according to pain response pattern after genicular nerve block: non-response, defined as less than 50% reduction in VAS pain score at 1 month; transient response, defined as at least 50% reduction at 1 month but less than 50% reduction at 3 months; and sustained response, defined as at least 50% reduction at both 1 and 3 months. The association between baseline STAR and responder pattern will be evaluated.

    Time frame: 1 month, and 3 months

  2. WOMAC Score

    The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a self-administered questionnaire used to evaluate knee and hip osteoarthritis. The global score ranges from 0 to 96, where 0 represents the best possible outcome (no pain or functional limitations) and 96 represents the worst possible outcome (severe pain and maximal functional limitations). Higher scores indicate a worse clinical outcome.

    Time frame: Baseline, 1 month, and 3 months

  3. Five Times Sit-to-Stand Test

    Change in functional performance assessed using the Five Times Sit-to-Stand (5xSTS) test. The Five Times Sit-to-Stand (5xSTS) test assesses functional lower extremity strength and transitional movements. The outcome is recorded as the total time (in seconds) required for the participant to complete five consecutive sit-to-stand cycles as quickly as possible from a standard chair. The minimum possible time is 0 seconds, and a maximum cutoff score of 30 seconds is applied for participants who are unable to complete the task. Higher scores (longer times) indicate a worse outcome (poorer functional performance and lower extremity strength).

    Time frame: Baseline, 1 month, and 3 months

  4. Change in Pain Intensity

    Change in Visual Analog Scale (VAS) pain score from baseline after ultrasound-guided genicular nerve block. Pain intensity is assessed using the Visual Analog Scale (VAS). The scale consists of a horizontal line where the minimum value is 0 (representing "no pain") and the maximum value is 10 (representing "the worst possible pain"). Participants mark their current pain level on this line. Higher scores indicate a worse outcome (greater pain intensity).

    Time frame: Baseline, 1 month, and 3 months

07

Study locations

1 of 1 sites recruiting
  • University of Health Sciences Gaziosmanpaşa Physical Therapy and Rehabilitation Training and Research Hospital
    Istanbul, 34255, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Vilchez-Cavazos F, Gamboa Alonso AA, Simental-Mendia M, Pena-Martinez VM, Acosta-Olivo CA, Villarreal-Villarreal GA. Genicular Nerve Block for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Clin J Pain. 2024 Oct 1;40(10):618-624. doi: 10.1097/AJP.0000000000001240. PubMed 39143682 ↗
  • Razaq S, Kara M, Ozcakar L. The Relationship Between Sarcopenic Obesity and Knee Osteoarthritis: The SARCOB Study. Eur J Rheumatol. 2023 Aug 18. doi: 10.5152/eurjrheum.. Online ahead of print. PubMed 37594394 ↗
  • Kara M, Kaymak B, Ata AM, Ozkal O, Kara O, Baki A, Sengul Aycicek G, Topuz S, Karahan S, Soylu AR, Cakir B, Halil M, Ozcakar L. STAR-Sonographic Thigh Adjustment Ratio: A Golden Formula for the Diagnosis of Sarcopenia. Am J Phys Med Rehabil. 2020 Oct;99(10):902-908. doi: 10.1097/PHM.0000000000001439. PubMed 32941253 ↗

Individual participant data

Plan to share: Undecided — The investigators have not yet made a final decision regarding individual participant data (IPD) sharing. Data sharing will be considered after study completion in accordance with institutional policies, ethical requirements, and applicable data protection regulations.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

Of 179 non-industry observational studies under Osteoarthritis, Knee, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 6 months is below that.

Counting every sponsor, half of 220 studies reached it within 24 months; a quarter within 13 and three quarters within 61.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start May 2026 → Aug 2026, primary completion Sep 2026 → Feb 2027 and completion Nov 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartActual
Aug 5, 2026was May 2026
Primary completionEst.
Feb 2027was Sep 2026
CompletionEst.
Feb 2027was Nov 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 15, 2026→Aug 5, 2026
Oct 20, 2026
Primary completion
Sep 2026→Feb 2027
Oct 20, 2026
Study completion
Nov 2026→Feb 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date May 15, 2026→Aug 5, 2026
    Primary completion Sep 2026→Feb 2027
    Study completion Nov 2026→Feb 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07712419
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Aug 5, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion